2026_Oct_CPHI_Milan_Leaderboard

Audrey Furness
Marketing Executive

Is this your profile?

About

Audrey Furness is Marketing Executive for ONdrugDelivery Magazine.

Contributions

Interview: A Structured Approach to the Eco-Design Process

Fabien De Coninck and Bruno Morchain discuss Aptar Pharma’s eco-design philosophy with ONdrugDelivery’s Guy Furness. They cover how Aptar Pharma has implemented lifecycle assessments as a key tool to elucidate the environmental footprint of the company’s rubber components for primary packaging for injectable systems, including how they tackled the unique challenges presented by the complex, proprietary formulations involved in elastomer component design.

More contributions

INDUSTRIALISATION

COMPANY SHOWCASE: PCI PHARMA SERVICES

PCI Pharma Services showcases its portfolio of drug delivery-relevant solutions, including: sterile fill-finish and lyophilisation; drug-device combination product design and development; packaging for injectables; and Speedsolutions™ supply chain simplification, and highlights plans for expansion.

CONFERENCE SHOWCASE

CONNECT IN PHARMA REPORT: FUTURE TRENDS IN DRUG DELIVERY DEVICES

A new report from the organisers of Connect in Pharma, “The Future of Pharma Production, Manufacturing and Packaging Trend Report”, has highlighted a range of forces shaping the future of the pharmaceutical manufacturing and drug-delivery industry.

Technology Showcase: Testing Solutions for pMDI Drug Development

Proveris Scientific showcases its complete suite of testing solutions for pMDI drug development, which include Proveris by Design, Ergo Studies, Vereo SFMDx Actuators, and a new Kinaero Cx pMDI Collection System.

PHARMAPACK EUROPE DRUG DELIVERY AND PACKAGING ANNUAL SURVEY 2021

Pharmapack presents the results of its annual survey and market report, covering the latest Pharmapack Innovation Index and the inaugural Pharmapack Sustainability Index, and taking stock of where the survey results suggest the pharma industry currently is, and where it is heading, in terms of innovation and sustainability.

MEDICAL DEVICE DESIGN STRATEGY FOR A CONNECTED FUTURE

Michael Kiely, Laura Marsden, Peter Stringer, and David Boyle discuss the design challenges at the electromechanical interface and encourage manufacturers to adopt a standardised approach for connecting medical devices to the cloud.

PREFILLED SYRINGES

TRAINING DEVICES & PATIENT EDUCATION PLAY A CRUCIAL ROLE IN THE SELF-INJECTION DRUG DELIVERY MARKET

Joe Reynolds discusses the role training devices and patient education play with regard to self-injection therapies.

ENHANCING PROTEIN PRESERVATION DURING BIOLOGICAL DRUG PREPARATION AND DELIVERY

Adrien Bouillet, Loïc Girois and Marianne Weidenhaupt, discuss the results of work carried out in joint efforts by EVEON and LMGP in the field of protein adsorption and aggregation, and how the results of this work have led to improvements in the design of EVEON’s proprietary micropump.

PREFILLED SYRINGES

THE IMPORTANCE OF A GREAT DEVELOPMENT EXPERIENCE TO ACHIEVE A GREAT MEDICAL DEVICE

William Fortina considers the importance of the medical device development experience in the healthcare context and discusses the factors that make for a superior development process.

INDUSTRIALISATION

PACKAGING LINE FOR GSK AUTOINJECTORS: A CASE STUDY

Ivan De Sanzo describes a unique automated complete packaging line provided to GlaxoSmithKline for three different autoinjectors.

MEETING THE CHALLENGES OF COVID-19

Beo Arana de Martinez and Ilan Shopen discuss the effects of the covid-19 pandemic on patient populations, how the healthcare industry has intensified activity to fight the virus, and how connected devices that facilitate self-injection and remote monitoring are coming into their own.

Senzer to Create Targeted Inhaled Antivirals for COVID-19

Senzer Pharmaceuticals has launched a Critical Care Division, which will utilise its expertise in respiratory pharmaceuticals to create targeted antiviral treatments for covid-19.

Covis Pharma’s Alvesco (ciclesonide) Inhaler Enters Phase III COVID-19 Trials

Covis Pharma's inhaled glucocorticoid, Alvesco (ciclesonide), has entered a US multicentre, randomised, double-blind, placebo-controlled Phase III safety and efficacy trial in 400 non-hospitalised patients 12 years of age and older with symptomatic covid-19. The product is delivered twice daily via a pMDI.

Stabilitech Recognised by WHO, seeks £6m funding to make oral SARS-COV-2 vaccine available by end of 2020

Stabilitech Biopharma, which is developing OraPro-COVID-19, an oral coronavirus vaccine, has been formally recognised on the international stage by the WHO as a vaccine developer, and seeks £6 million to fund clinical trials and manufacturing required to make the vaccine available by the end of 2020.

RedHill’s US IND Approved for Opaganib SARS-COV-2 trial; positive results from Israeli trial

RedHill Biopharma has received US FDA of its IND for a Phase IIa clinical trial of opaganib (Yeliva^®, ABC294640) in 40 hospitalised SARS-COV-2 patients, and has reported positive preliminary results from a trial of the product in six patients in Israel.

BAVARIAN NORDIC ENTERS AGREEMENT WITH ADAPTVAC TO ADVANCE COVID-19 VACCINE

Bavarian Nordic has entered into an exclusive head of terms agreement to license AdaptVac’s proprietary capsid virus like particle (VLP)-based SARS-CoV-2 subunit vaccine technology, to help a European consortium, PREVENT-nCoV, move towards clinical proof of concept. Bavarian Nordic takes responsibility for clinical development and global commercialisation of the vaccine.

KEY NOSE CELLS IDENTIFIED AS LIKELY COVID-19 VIRUS ENTRY POINTS

Researchers from the Human Cell Atlas Lung Biological Network, have identified two specific cell types in the nose as likely initial infection points for COVID-19 coronavirus, and cells in the eye and some other organs that also contain the viral-entry proteins. They also predict how a key entry protein is regulated with other immune system genes and reveals potential targets for the development of treatments to reduce transmission.

ARTES USING METAVAX^® AND SplitCore VLP PLATFORM FOR SARS-CoV-2 vaccine

ARTES Biotechnology has begun development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP)-based platform technologies METAVAX^® and SplitCore.

MedPharm Develops Model to Support Coronavirus Pharmaceutical Development

A new testing model from MedPharm supports pharmaceutical development programmes targeting coronavirus treatments, meaning companies can assess the therapeutic effectiveness of their anti-COVID-19 candidate compounds in nasal, airway (bronchial), and deep lung (alveolar) epithelia against members of the Coronaviridae family.

Squalene-based nanoparticles for the treatment of uncontrolled inflammatory processes

Nanoparticles developed by researchers from Galien Institute at Paris-Saclay University and the Federal University of Rio de Janeiro, made by conjugating squalene to adenosine and then encapsulating α-tocopherol, a natural antioxidant, have shown potential against the uncontrolled inflammatory processes associated with severe SARS-COV-2 infection.

Chitosan nanoparticles suitable for aerosol treatment of Covid-19 patients

Bioavanta-Bosti has developed of a 48-hour manufacturing process, using its Novochizol chitosan polysaccharide nanotechnology to encapsulate APIs – small molecules or biologics – for localised delivery and sustained release, to generate intra-pulmonary drug delivery formulations suitable for treating COVID-19 patients.

NanoPass Sharing Microneedle Device with Pharma Partners for COVID-19 Vaccine

NanoPass is sharing its proprietary MicronJet microneedle device with vaccine and immunotherapy companies to help in the efforts to develop a safe, effective and affordable vaccine against SARS-COV-2, novel coronavirus.

Pulmonary Delivery Could Make Niclosamide Effective Against COVID-19

A novel inhaled formulation of the approved antihelminthic drug, niclosamide, is under development at the College of Pharmacy at The University of Texas at Austin for COVID-19. The compound was recently confirmed to exhibit antiviral efficacy in SARS-COV-2 infected cells and indeed was more potent compared with chloroquine, lopinavir and remdesivir, the group said.

New Sensor Solution for Ventilators

Sensirion has launched a new flow sensor, SFM301, which has specifically been developed to be scaleable, and integrated easily into respiratory devices such as ventilators for the treatment of COVID-19 patients. The sensor is based on the company's CMOSens® technology, and can measure oxygen, and air.

1
2
3
Next

Top